title: Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial.
abstract: We performed a prospective study to investigate the efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone in non-Hodgkin lymphoma patients receiving R-CEOP or CEOP chemotherapy regimen. All patients were randomly assigned to either an aprepitant regimen (aprepitant plus ondansetron and prednisone), or a control regimen (ondansetron and prednisone) treatment group. For the complete response, the aprepitant group was statistically superior to the control group in the overall study period (76.5% vs. 56.0%; p = .03), as well as in separate analyses of the acute phase (92.2% vs. 78.0%; p = .045), and even more notably in the delayed phase (82.4% vs. 64.0%; p = .037). The overall incidence of adverse events was similar between the two treatment groups (p > .05). The aprepitant regimen was more effective than the control regimen for the prevention of CINV in patients receiving R-CEOP or CEOP regimen and was generally well tolerated.
authors.affiliation: a Department of Lymphoma , Tianjin Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital , Tianjin , China.
authors.forename: Zheng
authors.initials: Z
authors.lastname: Song
authors.affiliation: b Department of Oncology , Tianjin Union Medical Center , Tianjin , China.
authors.forename: Huaqing
authors.initials: H
authors.lastname: Wang
authors.affiliation: a Department of Lymphoma , Tianjin Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital , Tianjin , China.
authors.forename: Huilai
authors.initials: H
authors.lastname: Zhang
authors.affiliation: a Department of Lymphoma , Tianjin Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital , Tianjin , China.
authors.forename: Kuo
authors.initials: K
authors.lastname: Zhao
authors.affiliation: a Department of Lymphoma , Tianjin Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital , Tianjin , China.
authors.forename: Man
authors.initials: M
authors.lastname: Zhang
authors.affiliation: a Department of Lymphoma , Tianjin Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital , Tianjin , China.
authors.forename: Fang
authors.initials: F
authors.lastname: Yang
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D000077608:Aprepitant; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D009325:Nausea / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control*; D017294:Ondansetron / Q000009:adverse effects / Q000627:therapeutic use*; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D016896:Treatment Outcome; D014839:Vomiting / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control*
chemical_list: D009025:Morpholines; D000077608:Aprepitant; D017294:Ondansetron; D011241:Prednisone
keywords: Aprepitant; CEOP regimen; CINV; non-Hodgkin lymphoma